The Challenge of Inverted Duty
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has formally raised concerns regarding the persistent issue of inverted duty structures affecting Micro, Small, and Medium Enterprises (MSMEs) within the pharmaceutical sector. During a recent consultative session, Director General Raja Bhanu announced that the council is actively gathering feedback from member organizations to prepare a comprehensive representation for the Ministry of Chemicals and Fertilizers. This initiative aims to address the fiscal pressures that have hampered the competitiveness of smaller manufacturers throughout the current fiscal year.
Contextualizing the Fiscal Hurdle
An inverted duty structure occurs when the tax rate on inputs is higher than the tax rate on the final output. For pharma MSMEs, this creates a persistent accumulation of unutilized input tax credits, which effectively locks up working capital. While larger pharmaceutical corporations often possess the liquidity to absorb these costs, smaller players find their cash flows severely constrained, limiting their ability to invest in R&D or expansion.
The issue has gained renewed urgency following recent feedback regarding structural changes under the proposed GST 2.0 framework. As the government looks to streamline indirect taxation, industry stakeholders are pushing for a policy alignment that ensures the tax burden does not disproportionately fall on the value-addition process of smaller firms.
Impact on the Pharmaceutical Landscape
The pharmaceutical industry in India, often referred to as the ‘pharmacy of the world,’ relies heavily on a robust network of MSMEs for the supply of Active Pharmaceutical Ingredients (APIs) and intermediate formulations. Data from the Ministry of MSME indicates that these smaller units contribute significantly to both domestic affordability and export volumes. However, industry analysts note that the inverted duty structure forces these companies to operate on razor-thin margins.
According to Pharmexcil, the collective representation will emphasize the need for a simplified refund mechanism or a recalibration of duty slabs. Experts suggest that without such intervention, the cost of production for essential medicines could rise, potentially impacting the affordability of healthcare products for the end consumer. Furthermore, the volatility in raw material costs, coupled with tax inefficiencies, has created a challenging environment for maintaining export parity against global competitors.
Industry Perspectives and Representation
The council is currently consolidating data points from various regional clusters to present a data-driven case to the government. Member feedback suggests that the disparity in tax rates across different categories of inputs—specifically chemicals and solvents—is a primary driver of the current fiscal imbalance. By presenting a unified front, Pharmexcil hopes to expedite a review of the GST classifications that currently place smaller units at a disadvantage.
Looking Ahead: Future Policy Watch
The upcoming months will be critical for the pharmaceutical sector as the Ministry evaluates the industry’s proposal. Stakeholders are closely watching for any signals of a potential restructuring of GST slabs or a more efficient mechanism for duty drawback claims. Should the government move to rectify the inverted duty structure, it could provide a much-needed liquidity boost to the MSME sector, fostering increased investment in high-quality manufacturing standards. Moving forward, the industry anticipates a shift toward a more neutral tax environment that supports the ‘Make in India’ initiative while maintaining the global competitiveness of domestic pharmaceutical exports.
